PCVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PCVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Vaxcyte's Long-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.
The historical data trend for Vaxcyte's Long-Term Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaxcyte Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Long-Term Debt | Get a 7-Day Free Trial | - | - | - | - | - |
Vaxcyte Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Long-Term Debt | Get a 7-Day Free Trial | - | - | - | - | - |
Vaxcyte (NAS:PCVX) Long-Term Debt Explanation
Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.
Thank you for viewing the detailed overview of Vaxcyte's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Jim Wassil | officer: Chief Operating Officer | C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404 |
Grant Pickering | director, officer: President & CEO | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Andrew Guggenhime | officer: CFO, CBO | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Mikhail Eydelman | officer: SVP, Gen Counsel & Corp Sec | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070 |
Teri Loxam | director | C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472 |
Elvia Cowan | officer: See Remarks Section | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070 |
Halley E Gilbert | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Heath Lukatch | director | 326 BOLLAY DRIVE, GOLETA CA 93117 |
Jeff Fairman | officer: VP, Research | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Paul Sauer | officer: SVP Process Dev, Manufacturing | C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404 |
Michael E. Kamarck | director | C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406 |
Carlos V Paya | director | C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102 |
Harpreet S. Dhaliwal | officer: SVP Cml Mfg & Supply Chain | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Anne S Drapeau | director | C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110 |
Jane Wright Mitchell | officer: General Counsel | C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
From GuruFocus
By Marketwired • 09-11-2024
By Marketwired • 11-12-2024
By GuruFocus Research • 05-10-2024
By Marketwired • 12-03-2024
By GuruFocus News • 11-13-2024
By Marketwired • 09-05-2024
By Marketwired • 11-05-2024
By GuruFocus Research • 02-08-2024
By GuruFocus News • 11-15-2024
By GuruFocus Research • 03-20-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.